Anna A Brożyna1, Wojciech Jóźwicki2, Andrzej T Slominski3. 1. Department of Tumor Pathology and Pathomorphology, Oncology Centre, Prof. Franciszek Łukaszczyk Memorial Hospital, The Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland anna.brozyna@cm.umk.pl aslominski@uthsc.edu. 2. Department of Tumor Pathology and Pathomorphology, Oncology Centre, Prof. Franciszek Łukaszczyk Memorial Hospital, The Ludwik Rydygier Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. 3. Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN, U.S.A. Division of Dermatology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN, U.S.A. anna.brozyna@cm.umk.pl aslominski@uthsc.edu.
Abstract
BACKGROUND: Vitamin D3, acting via vitamin D receptor (VDR) affects a wide range of biological activities, including inhibition of proliferation and angiogenesis, with net antitumor effects. VDR expression is disturbed in many tumors, including melanomas. AIM: To find correlation between VDR expression in melanomas and prognostic biomarkers. MATERIALS AND METHODS: VDR was analyzed immunohistochemically in 69 cutaneous melanomas in relation to prognostic factors. RESULTS: Less advanced melanomas showed significantly higher VDR expression than the advanced stages. The presence of other markers such as ulceration and lack or non-brisk tumor infiltrating lymphocytes (TILs) was accompanied by significantly lower VDR expression. VDR expression also affected overall survival (OS) with most noticeable effect in the cases without ulceration. CONCLUSION: High VDR expression determines a less malignant phenotype and is related to better prognosis. Loss of VDR expression affects melanoma tumor behavior, allowing for progression of disease. VDR expression can also serve as a prognostic marker in routine histopathology evaluation. Copyright
BACKGROUND:Vitamin D3, acting via vitamin D receptor (VDR) affects a wide range of biological activities, including inhibition of proliferation and angiogenesis, with net antitumor effects. VDR expression is disturbed in many tumors, including melanomas. AIM: To find correlation between VDR expression in melanomas and prognostic biomarkers. MATERIALS AND METHODS:VDR was analyzed immunohistochemically in 69 cutaneous melanomas in relation to prognostic factors. RESULTS: Less advanced melanomas showed significantly higher VDR expression than the advanced stages. The presence of other markers such as ulceration and lack or non-brisk tumor infiltrating lymphocytes (TILs) was accompanied by significantly lower VDR expression. VDR expression also affected overall survival (OS) with most noticeable effect in the cases without ulceration. CONCLUSION: High VDR expression determines a less malignant phenotype and is related to better prognosis. Loss of VDR expression affects melanoma tumor behavior, allowing for progression of disease. VDR expression can also serve as a prognostic marker in routine histopathology evaluation. Copyright
Authors: Jin Wang; Andrzej Slominski; Robert C Tuckey; Zorica Janjetovic; Anand Kulkarni; Jianjun Chen; Arnold E Postlethwaite; Duane Miller; Wei Li Journal: Anticancer Res Date: 2012-03 Impact factor: 2.480
Authors: Andrzej T Slominski; Michal A Zmijewski; Cezary Skobowiat; Blazej Zbytek; Radomir M Slominski; Jeffery D Steketee Journal: Adv Anat Embryol Cell Biol Date: 2012 Impact factor: 1.231
Authors: Andrzej T Slominski; Tae-Kang Kim; Zorica Janjetovic; Robert C Tuckey; Radoslaw Bieniek; Junming Yue; Wei Li; Jianjun Chen; Minh N Nguyen; Edith K Y Tang; Duane Miller; Tai C Chen; Michael Holick Journal: Am J Physiol Cell Physiol Date: 2010-12-15 Impact factor: 4.249
Authors: Alison L Burton; Brent A Roach; Michael P Mays; Andrea F Chen; Brooke A R Ginter; Abbey M Vierling; Charles R Scoggins; Robert C G Martin; Arnold J Stromberg; Lee Hagendoorn; Kelly M McMasters Journal: Am Surg Date: 2011-02 Impact factor: 0.688
Authors: Z Janjetovic; A A Brozyna; R C Tuckey; T-K Kim; M N Nguyen; W Jozwicki; S R Pfeffer; L M Pfeffer; A T Slominski Journal: Br J Cancer Date: 2011-11-17 Impact factor: 7.640
Authors: Andrzej T Slominski; Anna A Brożyna; Michal A Zmijewski; Wojciech Jóźwicki; Anton M Jetten; Rebecca S Mason; Robert C Tuckey; Craig A Elmets Journal: Lab Invest Date: 2017-02-20 Impact factor: 5.662
Authors: Andrzej T Slominski; Anna A Brożyna; Michal A Zmijewski; Zorica Janjetovic; Tae-Kang Kim; Radomir M Slominski; Robert C Tuckey; Rebecca S Mason; Anton M Jetten; Purushotham Guroji; Jörg Reichrath; Craig Elmets; Mohammad Athar Journal: Adv Exp Med Biol Date: 2020 Impact factor: 2.622
Authors: Irene Orlow; Yang Shi; Peter A Kanetsky; Nancy E Thomas; Li Luo; Sergio Corrales-Guerrero; Anne E Cust; Lidia Sacchetto; Roberto Zanetti; Stefano Rosso; Bruce K Armstrong; Terence Dwyer; Alison Venn; Richard P Gallagher; Stephen B Gruber; Loraine D Marrett; Hoda Anton-Culver; Klaus Busam; Colin B Begg; Marianne Berwick Journal: Pigment Cell Melanoma Res Date: 2017-11-05 Impact factor: 4.693
Authors: Irene Orlow; Anne S Reiner; Nancy E Thomas; Pampa Roy; Peter A Kanetsky; Li Luo; Susan Paine; Bruce K Armstrong; Anne Kricker; Loraine D Marrett; Stefano Rosso; Roberto Zanetti; Stephen B Gruber; Hoda Anton-Culver; Richard P Gallagher; Terence Dwyer; Klaus Busam; Colin B Begg; Marianne Berwick Journal: Carcinogenesis Date: 2015-10-31 Impact factor: 4.944
Authors: Andrzej T Slominski; Anna A Brożyna; Cezary Skobowiat; Michal A Zmijewski; Tae-Kang Kim; Zorica Janjetovic; Allen S Oak; Wojciech Jozwicki; Anton M Jetten; Rebecca S Mason; Craig Elmets; We Li; Robert M Hoffman; Robert C Tuckey Journal: J Steroid Biochem Mol Biol Date: 2017-07-01 Impact factor: 4.292
Authors: Kara A DeSantis; Samantha L Robilotto; Mark Matson; Noor M Kotb; Cathryn M Lapierre; Zenab Minhas; Alana A Leder; Khushbakht Abdul; Emily M Facteau; JoEllen Welsh Journal: J Steroid Biochem Mol Biol Date: 2020-01-17 Impact factor: 4.292